Cargando…
Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer
Peripheral neuropathy is a common side effect of chemotherapeutic agents that frequently necessitates dose-reduction, truncation of, or change in therapy. HDAC6 inhibition has demonstrated preclinical efficacy in preventing and/or reversing chemotherapy-induced peripheral neuropathy and furthermore...
Autores principales: | Lee, Elizabeth K., Tan-Wasielewski, Zhenying, Matulonis, Ursula A., Birrer, Michael J., Wright, Alexi A., Horowitz, Neil, Konstantinopoulos, Panagiotis A., Curtis, Jennifer, Liu, Joyce F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6712364/ https://www.ncbi.nlm.nih.gov/pubmed/31467965 http://dx.doi.org/10.1016/j.gore.2019.07.010 |
Ejemplares similares
-
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
por: Lee, Elizabeth K., et al.
Publicado: (2020) -
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
por: Fu, Siqing, et al.
Publicado: (2022) -
Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine
por: Cosenza, Maria, et al.
Publicado: (2017) -
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008) -
Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer
por: Konstantinopoulos, Panagiotis A., et al.
Publicado: (2013)